Gardnerella vaginalis adhesion sites on vaginal epithelial cells

Gardnerella vaginalis adhesion sites on vaginal epithelial cells are the molecular interfaces that facilitate the colonization and pathogenesis of G. vaginalis, the primary bacterium associated with bacterial vaginosis (BV). The most prominent identified site is the human-specific membrane protein CD59, which serves as the receptor for vaginolysin (VLY), a cholesterol-dependent cytolysin that forms pores in the host cell membrane [1][2]. Beyond CD59, G. vaginalis utilizes various adhesins to interact with extracellular matrix components such as fibronectin and laminin, as well as cell-surface proteoglycans like syndecan-1, to establish dense, multi-species biofilms [3][4]. These adhesion events lead to the formation of 'clue cells,' which are vaginal epithelial cells heavily encrusted with bacteria, a hallmark of BV diagnosis [5]. While current clinical management relies on antibiotics like metronidazole and clindamycin to reduce the bacterial population, these agents do not specifically target the host-pathogen adhesion interface and are often associated with high rates of recurrence [6]. Emerging therapeutic research is exploring the use of anti-adhesion agents, such as small molecules or antibodies that competitively inhibit the binding of bacterial toxins to host receptors, to provide more targeted and sustainable treatment options [7]. Sources: [1] Gelber SE, et al. (2008) J Bacteriol; [2] Zilnyte M, et al. (2015) Sci Rep; [3] Machado A, et al. (2015) Pathog Dis; [4] Patterson JL, et al. (2010) Microbiology; [5] StatPearls (2023) Bacterial Vaginosis; [6] Muzny CA, et al. (2019) Curr Infect Dis Rep; [7] Rosca AS, et al. (2020) Front Cell Infect Microbiol.

Other names

Vaginal epithelial cell receptors for Gardnerella vaginalisG. vaginalis host cell attachment sitesVEC adhesion receptorsVaginolysin receptors

Standard treatments involve bactericidal or bacteriostatic action against Gardnerella vaginalis to prevent its attachment and biofilm formation; experimental strategies focus on blocking the interaction between bacterial vaginolysin and host CD59 receptors.